Induced and natural regulatory T cells in human cancer

Bibliography

• Mougiakakos D, Choudhury A, Lladser A, Regulatory T cells in cancer. Adv Cancer Res 2010;107:57-117
   PubMed Web of Science ®Google Scholar
• Allan SE, Broady R, Gregori S, CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008;223:391-421
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
   PubMed Web of Science ®Google Scholar
• Bettini M, Vignali D. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol 2009;21:612-18
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67
   PubMed Web of Science ®Google Scholar
• Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009;30:646-55
   PubMed Web of Science ®Google Scholar
• Duarte JH, Zelenay S, Bergman ML, Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009;39:948-55
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Bacchetta R, Bordignon C, Type 1 T regulatory cells. Immunol Rev 2001;182:68-79
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2011;61:283-8
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin MA. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest 2007;117:1175-83
   PubMed Web of Science ®Google Scholar
• Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010;238:247-62
   PubMed Web of Science ®Google Scholar
• Trifari S, Kaplan CD, Tran EH, Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-71
   PubMed Web of Science ®Google Scholar
• Duhen T, Geiger R, Jarrossay D, Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Lanzavecchia A, Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector TH cells. Blood 2012; published online 21 March 2012; doi:10.1182/blood-2011-11-392324
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay CR, Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875-83
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor-alpha chains (CD25). Breakdown of a single mechanism of self tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64
   PubMed Web of Science ®Google Scholar
• Gavin MA, Rasmussen JP, Fontenot JD, Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007;445:771-5
   PubMed Web of Science ®Google Scholar
• Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect 2004;6:745-51
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-87
   PubMed Web of Science ®Google Scholar
• Canavan JB, Afzali B, Scotta C, A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012;119:e57-66
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-7
   PubMed Web of Science ®Google Scholar
• Karanikas V, Speletas M, Zamanakou M, Foxp3 expression in human cancer cells. J Transl Med 2008;6:19
   PubMed Web of Science ®Google Scholar
• Wang J, Ioan-Facsinay A, van der Voort EI, Transient expression of Foxp3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007;37:129-38
   PubMed Web of Science ®Google Scholar
• Toker A, Huehn J. To be or not to be a Treg cell: lineage decisions controlled by epigenetic mechanisms. Sci Signal 2011;4:pe4
   PubMed Web of Science ®Google Scholar
• Polansky JK, Schreiber L, Thelemann C, Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl) 2010;88:1029-40
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121:2473-83
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK, Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int.Immunol 2007;19:345-54
   PubMed Web of Science ®Google Scholar
• Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008;224:166-82
   PubMed Web of Science ®Google Scholar
• Franceschini D, Paroli M, Francavilla V, PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009;119:551-64
   PubMed Web of Science ®Google Scholar
• McHugh RS, Whitters MJ, Piccirillo CA, CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-23
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski MJ, Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180:2967-80
   PubMed Web of Science ®Google Scholar
• Gobert M, Treilleux I, Bendriss-Vermare N, Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009;69:2000-9
   PubMed Web of Science ®Google Scholar
• Yuan Q, Bromley SK, Means TK, CCR4-dependent regulatory T cell function in inflammatory bowel disease. J Exp Med 2007;204:1327-34
   Google Scholar
• Kleinewietfeld M, Puentes F, Borsellino G, CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005;105:2877-86
   PubMed Web of Science ®Google Scholar
• Menning A, Hopken UE, Siegmund K, Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. Eur J Immunol 2007;37:1575-83
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Takahashi T, Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-42
   PubMed Web of Science ®Google Scholar
• Azuma M. Role of the glucocorticoid-induced TNFR-related protein (GITR)-GITR ligand pathway in innate and adaptive immunity. Crit Rev Immunol 2010;30:547-57
   PubMed Web of Science ®Google Scholar
• Thornton AM, Korty PE, Tran DQ, Expressio of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010;184:3433-41
   PubMed Web of Science ®Google Scholar
• Elkord E, Sharma S, Burt DJ, Hawkins RE. Expanded subpopulation of Foxp3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol 2011;140:218-22
   PubMed Web of Science ®Google Scholar
• Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol 2012;188:976-80
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-11
   PubMed Web of Science ®Google Scholar
• Kleinewietfeld M, Starke M, Di Mitri D, CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 2009;113:827-36
   PubMed Web of Science ®Google Scholar
• Peters JH, Preijers FW, Woestenenk R, Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation. PLoS One 2008;3:e3161
   PubMedGoogle Scholar
• Deaglio S, Dwyer KM, Gao W, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-65
   PubMed Web of Science ®Google Scholar
• Borsellino G, Kleinewietfeld M, DiMitri D, Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-32
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods 2009;346:55-63
   PubMed Web of Science ®Google Scholar
• Bynoe MS, Viret C. Foxp3+CD4+ T cell-mediated immunosuppression involves extracellular nucleotide catabolism. Trends Immunol 2008;29:99-102
   Google Scholar
• Dwyer KM, Hanidziar D, Putheti P, Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant 2010;10:2410-20
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski M, Harasymczuk M, CD26 expression and adenosine deaminase activity in regulatory T cells (Treg) and CD4+ T effector cells in patients with head and neck squamous cell carcinoma. Oncol Immunol 2012; In press
   Google Scholar
• Salgado FJ, Perez-Diaz A, Villanueva NM, CD26: a negative selection marker for human Treg cells. Cytometry A 2012; In press
   PubMed Web of Science ®Google Scholar
• Ohta A, Kini R, Ohta A, The development and immunosuppressive functions of CD4+CD25+FOXP3+ regulatory T cells are under influence of the adenosine-A2a adenosine receptor pathway. Frontiers in T Cell Biol 2012; In press
   Google Scholar
• Mandapathil M, Hilldorfer B, Szczepanski MJ, Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells (Treg). J Biol Chem 2010;285:7176-86
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Harasymczuk M, Schilling B, Separation of human CD4(+)CD39(+) T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods 2011;369:59-68
   PubMed Web of Science ®Google Scholar
• Schuler PJ, Schilling B, Harasymczuk M, Phenotypic and functional characteristics of ATP-hydrolysing CD+CD39+ Treg subsets in patients with cancer. Eur J Immunol 2012; In press
   PubMed Web of Science ®Google Scholar
• Moncrieffe H, Nistala K, Kamhieh Y, High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol 2010;185:134-43
   PubMed Web of Science ®Google Scholar
• Rittiner JE, Korboukh I, Hull-Ryde EA, AMP is an adenosine A1 receptor agonist. J Biol Chem 2012;287:5301-9
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Gooding W, The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-11
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Wang Y, T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008;14:3706-15
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol Immunother 2007;56:1429-42
   PubMed Web of Science ®Google Scholar
• Romio M, Reinbeck B, Bongardt S, Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol 2011;301:C530-9
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J Biol Chem 2010;285:27571-80
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-45
   PubMed Web of Science ®Google Scholar
• Czystowska M, Strauss L, Bergmann C, Reciprocal granzyme/perforin-mediated death of human regulatory and responder T cells is regulated by interleukin-2 (IL-2). J Mol Med 2010;88:577-88
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ Treg kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469-80
   PubMed Web of Science ®Google Scholar
• Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression – a diverse arsenal for a moving target. Immunology 2008;124:13-22
   PubMed Web of Science ®Google Scholar
• Maecker HT, Maino VC. Analysing T cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 2004;65:493-9
   PubMed Web of Science ®Google Scholar
• Han Q, Bagheri N, Bradshaw EM, Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci USA 2012;109:1607-12
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Weis EM, Human regulatory T cells rapidly suppress T cell-receptor-induced Ca2+, NF-kappaB, and NFAT signaling in conventional T cells. Sci Signal 2011;4:ra 90
   Google Scholar
• Strauss L, Bergmann C, Szczepanski M, A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-10 and TGF-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13:4345-54
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67:8865-73
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Szczepanski MJ, Szajnik M, Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009;15:6348-57
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Whiteside TL. Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E2 cooperation. Expert Opin Biol Ther 2011;11:1203-14
   PubMed Web of Science ®Google Scholar
• Zarek PE, Powell JP. Adenosine and anergy. Autoimmunity 2007;40:425-32
   PubMed Web of Science ®Google Scholar
• Schenk U, Frascoli M, Proietti M, ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Sci Signal 2011;4:ra12
   PubMed Web of Science ®Google Scholar
• Schulze Zur Wiesch J, Thomssen A, Hartjen P, Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FOXP3+ Tregulatory cells correlates with progressive disease. J Virol 2011;85:1287-97
   PubMed Web of Science ®Google Scholar
• Martin F, Ladoire Mignot G, Human FOXP3 and cancer. Oncogene 2010;29:4121-9
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80
   PubMed Web of Science ®Google Scholar
• Fridman WH, Galon J, Pages F, Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011;71:5601-5
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Miecnik B, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64
   PubMed Web of Science ®Google Scholar
• Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011;60:909-18
   PubMed Web of Science ®Google Scholar
• Badoual C, Hans S, Rodriquez J, Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 2006;12:465-72
   PubMed Web of Science ®Google Scholar
• Ercolini AM, Ladle BH, Manning EA, Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:1591-602
   PubMed Web of Science ®Google Scholar
• Audia SA, Nicolas D, Cathelin N, Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 2007;150:523-30
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8
   PubMed Web of Science ®Google Scholar
• Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009;1174:99-106
   PubMed Web of Science ®Google Scholar
• Hobeika AC, Morse MA, Osada T, Depletion of human regulatory T cells. Methods Mol Biol 2011;707:219-31
   PubMedGoogle Scholar
• Finke JH, Rini B, Ireland J, Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Castelli C, Huygens C, Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res 2011;17:841-8
   PubMedGoogle Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33:435-41
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Mandapathil M, Schuler P. The Role of the Adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem 2011;18:5217-23
   PubMed Web of Science ®Google Scholar
• Strauss L, Czystowska M, Szajnik M, Differential responses of human regulatory T cells (Treg) and effector cells to rapamycin. PLoS One 2009;4:e5994
   PubMedGoogle Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Simeone E, Sznol M, Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37:508-16
   PubMed Web of Science ®Google Scholar
• Cohen AD, Schaer DA, Liu C, Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010;5:e10436
   PubMed Web of Science ®Google Scholar
• Nair S, Boczkowski D, Fassnacht M, Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007;67:371-80
   PubMed Web of Science ®Google Scholar
• Conroy H, Galvin KC, Higgins SC, Mills KH. Gene silencing of TGF-beta1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother 2012;61:425-31
   PubMed Web of Science ®Google Scholar
• Schilling B, Harasymczuk M, Schuler P, IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med (Berl) 2012;90:139-47
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012;61:283-8
   PubMed Web of Science ®Google Scholar